TY  - JOUR
T1  - Nörolojik Hastalıklarda Beş Yıllık Plazma Değişim Deneyimi, Tek Merkez Çalışması
TT  - Five Years Plasma Exchange Experience In Neurological Diseases, Single Center Study
AU  - Ergül, Metin
AU  - Zengin Acemoğlu, Şerife Şeyda
AU  - Aygün, Kemal
AU  - Başoğlu, Elif Işınsu
AU  - Gökmen Sevindik, Ömür
AU  - Demirkıran, Fatih
PY  - 2025
DA  - January
Y2  - 2024
DO  - 10.32708/uutfd.1584013
JF  - Journal of Uludağ University Medical Faculty
JO  - Uludağ Tıp Derg
PB  - Bursa Uludağ University
WT  - DergiPark
SN  - 1300-414X
SP  - 531
EP  - 536
VL  - 50
IS  - 3
LA  - tr
AB  - Terapötik plazmaferez değişimi (TPD) tedavisi birçok nörolojik hastalıkta başarıyla kullanılmaktadır. Merkezimizde TPD çeşitli diğer hastalıkların yanı sıra birçok nörolojik vakada kullanılmaktadır. Bu çalışmada, Ocak 2010 ile Aralık 2014 arasında TPD uygulanan hastaların verileri analiz edildi. Toplamda 775 seans, 114 siklus ve 86 hastanın verileri değerlendirildi ve analiz edildi. Ortanca yaş 49,8 idi. 75 hasta nöroloji bölümünde, 11 hasta ise dahiliye yoğun bakım ünitesi'nde takip edildi. Plazmaferez için en sık endikasyonlar myastenia gravis, multipl skleroz ve polinöropatilerdi (sırasıyla %35, %21, %9.3). TPD'de replasman sıvısı olarak Taze Donmuş Plazma (TDP) kullanılanlarda albumin kullanılanlara göre çok daha az hipotansiyon gelişti [sırasıyla 2 (%0.9);25(%4.4)](p
KW  - Plazmaferezin komplikasyonları
KW  - Myastenia gravis
KW  - Nörolojik hastalıklar
KW  - Plazma Değişimi
N2  - Therapeutic plasmapheresis exchange (TPE) treatment is used successfully in many neurological diseases. At our center, TPE is used in many neurological cases in addition to various other diseases. In this study, data of patients who underwent TPE between January 2010 and December 2014 were analyzed. In total, 775 sessions, 114 cycles, and 86 patients’ date were evaluated and analyzed. The median age was 49.8 years. 75 patients were followed in the neurology department and 11 patients were followed in the internal medicine intensive care unit. The most common indications for plasmapheresis were myasthenia gravis, multiple sclerosis, and polyneuropathies (respectively, %35, %21, %9.3). In TPE, hypotension developed much less in those using Fresh Frozen Plasma (FFP) as replacement fluid compared to those using albumin [respectively, 2 (%0.9); 25(%4.4)] (p
CR  - 1.Ergül M. Eren N. Acil Plazmaferez Gereksinimi; Güngör Ö. Arıcı M. Odabaş AR. Olgularla Nefrolojik Aciller. 1. Baskı. Ankara Nobel Tıp Kitapevi; 2023; 305-312.
CR  - 2.Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019 Jun;34(3):171-354.
CR  - 3.Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016 Jun;31(3):149-162.
CR  - 4.Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013 Jul;28(3):145-284.
CR  - 5.Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al. Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25(3):83-177.
CR  - 6.Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and
Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011 Jan 18;76(3):294-300.
CR  - 7.Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial. 2005 Oct;9(5):391-5.
CR  - 8.Som S, Deford CC, Kaiser ML, Terrell DR, Kremer Hovinga JA, Lämmle B, et al. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion. 2012 Dec;52(12):2525-32; quiz 2524.
CR  - 9.McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010;34(3):171-83.
CR  - 10.Bershad EM, Feen ES, Suarez JI. Myasthenia gravis crisis. South Med J. 2008 Jan;101(1):63-9.
CR  - 11.Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002;2002(4):CD002275.
CR  - 12.Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010 Dec;68(6):797-805.
CR  - 13.Marrodan M, Crema S, Rubstein A, Alessandro L, Fernandez J, Correale J, et al. Therapeutic plasma exchange in MS refractory relapses: Long-term outcome. Mult Scler Relat Disord. 2021 Oct;55:103168.
CR  - 14.Farooqi MS, Lai Y, Lancaster E, Schmitt SE, Sachais BS. Therapeutic plasma exchange and immunosuppressive therapy in a patient with anti-GAD antibody-related epilepsy: quantification of the antibody response. J Clin Apher. 2015 Feb;30(1):8-14.
UR  - https://doi.org/10.32708/uutfd.1584013
L1  - https://dergipark.org.tr/en/download/article-file/4360930
ER  -